Nymox Pharmaceutical Corp (NYMX) Director James George Robinson Buys 7,000 Shares

Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director James George Robinson acquired 7,000 shares of the stock in a transaction that occurred on Thursday, November 29th. The stock was acquired at an average cost of $1.81 per share, with a total value of $12,670.00. Following the completion of the purchase, the director now owns 3,265,913 shares of the company’s stock, valued at $5,911,302.53. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

James George Robinson also recently made the following trade(s):

  • On Tuesday, November 27th, James George Robinson acquired 8,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.71 per share, with a total value of $13,680.00.
  • On Friday, November 16th, James George Robinson acquired 6,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.93 per share, with a total value of $11,580.00.
  • On Tuesday, November 20th, James George Robinson acquired 6,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.78 per share, with a total value of $10,680.00.
  • On Tuesday, November 13th, James George Robinson acquired 7,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $2.00 per share, with a total value of $14,000.00.
  • On Friday, November 9th, James George Robinson acquired 13,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $2.09 per share, with a total value of $27,170.00.
  • On Wednesday, November 7th, James George Robinson acquired 363 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $2.04 per share, with a total value of $740.52.
  • On Friday, November 2nd, James George Robinson acquired 7,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.98 per share, with a total value of $13,860.00.
  • On Wednesday, October 31st, James George Robinson acquired 12,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.79 per share, with a total value of $21,480.00.
  • On Thursday, October 25th, James George Robinson acquired 10,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $16,200.00.
  • On Monday, October 22nd, James George Robinson acquired 8,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.67 per share, with a total value of $13,360.00.

NASDAQ:NYMX traded up $0.04 during mid-day trading on Friday, reaching $1.85. The company’s stock had a trading volume of 1,336 shares, compared to its average volume of 80,305. Nymox Pharmaceutical Corp has a 1 year low of $1.49 and a 1 year high of $4.60.

Nymox Pharmaceutical (NASDAQ:NYMX) last released its quarterly earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. Nymox Pharmaceutical had a negative net margin of 2,909.61% and a negative return on equity of 863.35%.

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in shares of Nymox Pharmaceutical by 648.6% during the second quarter. Bank of America Corp DE now owns 58,623 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 50,792 shares during the last quarter. BlackRock Inc. lifted its position in shares of Nymox Pharmaceutical by 22.7% during the second quarter. BlackRock Inc. now owns 1,618,459 shares of the biopharmaceutical company’s stock valued at $5,437,000 after buying an additional 299,752 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Nymox Pharmaceutical by 8.7% during the second quarter. Northern Trust Corp now owns 272,825 shares of the biopharmaceutical company’s stock valued at $916,000 after buying an additional 21,828 shares during the last quarter. 7.21% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Nymox Pharmaceutical Corp (NYMX) Director James George Robinson Buys 7,000 Shares” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/11/30/nymox-pharmaceutical-corp-nymx-director-james-george-robinson-buys-7000-shares.html.

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Featured Article: Why do earnings reports matter?

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit